On Thursday, Shares of Kindred Healthcare, Inc (NYSE:KND), lost -18.94% to $11.81.
KND, latest closing price of $11.81 is at a discount to its 200-day moving average price of $19.89. Its 52-week range has been $11.15 - $24.66; it is trading at discount versus its 52-week high of $24.66 achieved on Apr 27, 2015 and a premium to its 52-week low of $11.15 faced on Nov 5, 2015. The stock, as of recent close, has shown weekly downbeat performance of -10.19% which was maintained at -45.7% in this year.
The mean estimate for the short term price target for Kindred Healthcare, Inc (NYSE:KND), stands at $26.59 according to 8 Analysts. The higher price target estimate for the stock has been calculated at $42.00 while the lower price target estimate is at $16.75.
Analysts mean recommendation for the stock is 2.50. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Kindred Healthcare, Inc. provides healthcare services in the United States. It operates in four divisions: Hospital, Nursing Center, Rehabilitation, and Care Administration. The Hospital division operates transitional care hospitals that provide services for medically complex patients, counting the critically ill, suffering from multiple organ system failures, primarily the cardiovascular, pulmonary, kidney, gastro-intestinal, and cutaneous systems. This division also operates inpatient rehabilitation hospitals, which offer services to patients who require intensive inpatient rehabilitative care.
Shares of Horizon Pharma PLC (NASDAQ:HZNP), inclined 2.68% to $17.26, during its last trading session.
HZNP, has dropped -56.29% from its peak and trades at just 9.17 times forward earnings projections. The consensus price target for the stock is $40.89 a share. The 52-week range is $11.87 to $39.49. Up 35.91% over 12 months, the company has a market cap of $2.68 billion; its shares recently traded at around $17.26.
The mean estimate for the short term price target for Horizon Pharma PLC (NASDAQ:HZNP), stands at $40.89 according to 9 Analysts. The higher price target estimate for the stock has been calculated at $51.00 while the lower price target estimate is at $32.00.
Analysts mean recommendation for the stock is 1.90. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally.
Finally, Shares of Immunomedics, Inc (NASDAQ:IMMU), ended its last trade with 1.01% gain, and closed at $3.00.
IMMU, has $281.18 million in market value and its institutional ownership was 43.50%. The company has P/S ratio of 49.83 while its P/C ratio was 2.85. ROE was booked as -425.70% while ROI was -49.90%. Stock volatility was 7.84% and 8.92% for week and month respectively.
The mean estimate for the short term price target for Immunomedics, Inc (NASDAQ:IMMU), stands at $2.00 according to 1 Analysts. The higher price target estimate for the stock has been calculated at $2.00 while the lower price target estimate is at $2.00.
Analysts mean recommendation for the stock is 2.00. This number is based on a 1 to 5 scale where 1 indicates a Strong Buy recommendation while 5 represents a Strong Sell.
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other diseases. The company is developing Yttrium-90-labeled clivatuzumab tetraxetan, which is in Phase III registration study used for the treatment of pancreatic cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
